Alectinib for ALK-positive non-small-cell lung cancer

被引：23

作者：

Rossi, Antonio ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, Contrada Amoretta 8, I-83100 Avellino, Italy

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 08期

关键词：

Alectinib; ALK; brigatinib; ceritinib; crizotinib; NSCLC; resistance; TKI; MULTICENTER PHASE-II; POTENT ANTITUMOR-ACTIVITY; ADULT PATIENTS PTS; ANAPLASTIC LYMPHOMA; BRAIN METASTASES; OPEN-LABEL; INHIBITOR ALECTINIB; SINGLE-ARM; ACQUIRED-RESISTANCE; CERITINIB LDK378;

D O I：

10.1080/17512433.2016.1195262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Anaplastic lymphoma kinase (ALK) rearrangements are present in about 5% of advanced non-small-cell lung cancer (NSCLC) patients. Despite the initial response, after a median of 1-2years, ALK-positive patients developed an acquired resistance to the ALK-inhibitor crizotinib. Among the most promising second-generation ALK-inhibitors, alectinib is being investigated in crizotinib-naive and -resistant ALK-positive NSCLC patients.Areas covered: The current state-of-the-art of ALK-inhibitors treatment, and in particular the role of alectinib in this setting, is reviewed and discussed. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken.Expert commentary: Alectinib reports promising results with a good safety profile, becoming a potentially very important option for ALK-translocated NSCLC patients. The preliminary results from the J-ALEX phase III randomized trial performed in ALK-rearranged NSCLC Japanese patients showed a better activity and tolerability of alectinib versus crizotinib.

引用

页码：1005 / 1013

页数：9

共 63 条

[1] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].

Barlesi, Fabrice ;

Mazieres, Julien ;

Merlio, Jean-Philippe ;

Debieuvre, Didier ;

Mosser, Jean ;

Lena, Herve ;

Ouafik, L'Houcine ;

Besse, Benjamin ;

Rouquette, Isabelle ;

Westeel, Virginie ;

Escande, Fabienne ;

Monnet, Isabelle ;

Lemoine, Antoinette ;

Veillon, Remi ;

Blons, Helene ;

Audigier-Valette, Clarisse ;

Bringuier, Pierre-Paul ;

Lamy, Regine ;

Beau-Faller, Michele ;

Pujol, Jean-Louis ;

Sabourin, Jean-Christophe ;

Penault-Llorca, Frederique ;

Denis, Marc G. ;

Lantuejoul, Sylvie ;

Morin, Franck ;

Quan Tran ;

Missy, Pascale ;

Langlais, Alexandra ;

Milleron, Bernard ;

Cadranel, Jacques ;

Soria, Jean-Charles ;

Zalcman, Gerard .

LANCET, 2016, 387 (10026) :1415-1426

[2]

Camidge DR, 2015, J CLIN ONCOL, V33

[3] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[4] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].

Camidge, D. Ross ;

Kono, Scott A. ;

Flacco, Antonella ;

Tan, Aik-Choon ;

Doebele, Robert C. ;

Zhou, Qing ;

Crino, Lucio ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590

[5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[6] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

[7] Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent [J].

Conklin, Chris M. J. ;

Craddock, Kenneth J. ;

Have, Cherry ;

Laskin, Janessa ;

Couture, Christian ;

Ionescu, Diana N. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :45-51

[8] Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) [J].

Cui, J. Jean ;

Tran-Dube, Michelle ;

Shen, Hong ;

Nambu, Mitchell ;

Kung, Pei-Pei ;

Pairish, Mason ;

Jia, Lei ;

Meng, Jerry ;

Funk, Lee ;

Botrous, Iriny ;

McTigue, Michele ;

Grodsky, Neil ;

Ryan, Kevin ;

Padrique, Ellen ;

Alton, Gordon ;

Timofeevski, Sergei ;

Yamazaki, Shinji ;

Li, Quhua ;

Zou, Helen ;

Christensen, James ;

Mroczkowski, Barbara ;

Bender, Steve ;

Kania, Robert S. ;

Edwards, Martin P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6342-6363

[9] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[10] Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells [J].

Dong, Xuyuan ;

Fernandez-Salas, Ester ;

Li, Enxiao ;

Wang, Shaomeng .

NEOPLASIA, 2016, 18 (03) :162-171

← 1 2 3 4 5 6 7 →